Overview

A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection

Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the Dose from the safety and tolerability of intravenous Brincidofovir (BCV, SyB V-1901) on multiple ascending doses in subjects with Adenovirus infection.
Phase:
Phase 2
Details
Lead Sponsor:
SymBio Pharmaceuticals